DRI Healthcare Trust (TSE:DHT.UN) Stock Rating Lowered by Stifel Nicolaus

DRI Healthcare Trust (TSE:DHT.UNGet Free Report) was downgraded by investment analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Tuesday, BayStreet.CA reports. They presently have a C$15.00 target price on the stock, down from their prior target price of C$22.00. Stifel Nicolaus’ price objective would indicate a potential upside of 22.25% from the company’s current price.

Several other analysts also recently weighed in on DHT.UN. Raymond James downgraded shares of DRI Healthcare Trust from a “strong-buy” rating to an “outperform” rating and set a C$24.00 target price on the stock. in a research report on Tuesday. National Bankshares decreased their price objective on shares of DRI Healthcare Trust from C$23.50 to C$17.50 and set an “outperform” rating for the company in a research note on Tuesday. Royal Bank of Canada decreased their price objective on shares of DRI Healthcare Trust from C$20.00 to C$16.00 in a research note on Tuesday. CIBC decreased their price objective on shares of DRI Healthcare Trust from C$20.00 to C$18.50 in a research note on Tuesday. Finally, Canaccord Genuity Group decreased their price objective on shares of DRI Healthcare Trust from C$19.50 to C$19.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, DRI Healthcare Trust presently has a consensus rating of “Moderate Buy” and an average price target of C$19.14.

Check Out Our Latest Analysis on DHT.UN

DRI Healthcare Trust Price Performance

TSE:DHT.UN opened at C$12.27 on Tuesday. DRI Healthcare Trust has a twelve month low of C$10.21 and a twelve month high of C$17.43. The company’s 50 day moving average is C$15.03 and its two-hundred day moving average is C$14.92.

DRI Healthcare Trust Company Profile

(Get Free Report)

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.

See Also

Analyst Recommendations for DRI Healthcare Trust (TSE:DHT.UN)

Receive News & Ratings for DRI Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DRI Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.